A, Marberger M et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castrationresistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2014; 65: 875-883. 19. Smith MR, Rathkopf DE, Mulders PFA et al. Efficacy and safety of abiraterone acetate in elderly (≥75 years) chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. J Urol 2015; 194: 1277-1284. 20. Cleeland C. The brief pain inventory: user guide. http://www.mdanderson.org/ education-and-research/departments-programs-and-labs/departments-and-divisions/ symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf (8 February 2015, date last accessed). 21. Tinetti ME, Baker DI, King M et al. Effect of dissemination of evidence in reducing injuries from falls. N Engl J Med 2008; 359: 252-261. 22. Puts MT, Monette J, Girre V et al. The fall rate of older community-dwelling cancer patients. Support Care Cancer 2013; 21: 775-783. 23. Bylow K, Dale W, Mustian K et al. Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy. Urology 2008; 72: 422-427. 24. Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male 2005; 8: 207-212. 25. Woolcott JC, Richardson KJ, Wiens MO et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons.
introduction Up to 25% of all bladder cancer cases present with muscleinvasion, unresectable nodes or systemic metastases. Muscleinvasive bladder cancer has a poor prognosis with 5-year overall survival rates of only 40%-50% [1] . Advanced bladder cancer, defined as the presence of unresectable lymph node disease or metastatic visceral or bone deposits, is incurable and the median overall survival duration is around 14-16 months with palliative chemotherapy [2] .
For muscle-invasive bladder cancer, European guidelines recommend radical cystectomy with pelvic lymphadenectomy as the primary treatment of choice [3] . However, recent evidence suggests that a bladder preserving strategy with trans-urethral resection of bladder tumour followed by radical radiotherapy with a radiosensitizer offers an alternative that is in clinical equipoise with radical cystectomy [1, [4] [5] [6] [7] . In the UK, the National Institute of Health and Care Excellence guidelines on bladder cancer recommend a choice of either radical cystectomy or radiotherapy with a radiosensitizer to patients with muscleinvasive urothelial bladder [8] , and this is now a standard practice.
Tumour stage, completeness of trans-urethral resection of tumour and lymphovascular invasion are prognostic factors in muscle-invasive bladder cancer [1] . In advanced bladder cancer, poor performance status, low haemoglobin level and the presence of systemic metastases (visceral or bone) are associated with an inferior outcome [2] .
Pre-treatment lymphocytopaenia has been identified as a prognostic factor in several solid tumours, in particular metastatic breast, renal and colorectal cancer, although it has not been validated sufficiently to be of value in routine clinical practice [9] . Lymphocytopaenia may represent a state of cancer-induced immune incompetence which may limit tumour control following treatment with radiotherapy and chemotherapy [10, 11] . We chose a cohort of muscle-invasive urothelial bladder cancer patients treated with radical chemoradiotherapy as part of a bladder preservation strategy and a separate cohort of advanced urothelial bladder cancer patients treated with palliative chemotherapy to test the prognostic significance of pre-treatment lymphocytopaenia.
methods
The study was retrospective and included two cohorts of patients.
muscle-invasive bladder cancer cohort
This cohort comprised 74 muscle-invasive bladder cancer patients treated with radical chemoradiotherapy at a single comprehensive cancer centre in the UK.
These patients either opted for bladder preservation following a discussion with a urological surgeon and a clinical oncologist or were referred for radical chemoradiotherapy as they were deemed unsuitable for radical cystectomy.
All patients underwent trans-urethral resection of bladder tumour and received radical radiotherapy to a dose of 52.5 Gy with concomitant weekly gemcitabine at a dose of 100 mg/m 2 . Absolute lymphocyte count on the first day of treatment was obtained. Invasive local recurrence or systemic recurrence was defined as the survival end point. The median follow-up duration was 17 months (range 1-47 months).
advanced bladder cancer cohort
A total of 131 advanced urothelial bladder cancer patients treated with firstline palliative chemotherapy at our institution from 2009 to 2014 were included in this cohort. Gemcitabine with either cisplatin or carboplatin was the most commonly used chemotherapy schedule, whereas patients with prior exposure to this regime received accelerated MVAC (methotrexate, vinblastine, doxorubicin and cisplatin), docetaxel or paclitaxel with carboplatin. The median follow-up was 11 months (range 0.4-63 months).
Absolute lymphocyte count on the first day of chemotherapy was recorded with death defined as the survival end point. Overall survival was defined as time from the first day of the first cycle of palliative chemotherapy to death, with survivors censored at the time of last clinic review.
analysis. The statistical package R version 3.2.0 was used to analyse the data. A ROC curve was used to calculate the optimal cut-off to define lymphocytopaenia in the muscle-invasive bladder cancer cohort. Survival analyses were carried out using the Kaplan-Meier method and the data were compared using the Mantel-Cox log-rank test. Hazard ratios and 95% confidence intervals (CI) were obtained using Cox regression analysis. The prognostic factors used within the model in the muscle-invasive cohort were haemoglobin <120 g/l, neoadjuvant chemotherapy, absolute neutrophil count >7.5 × 10 9 /l, tumour stage and presence of hydronephrosis.
The prognostic factors included in the analysis of the advanced bladder cancer cohort were absolute lymphocyte count, absolute neutrophil count >7.5 × 10 9 /l, haemoglobin <120 g/l, performance status and presence of systemic visceral or bone metastases. Due to the larger number of events in this cohort, a second analysis evaluated the impact of absolute lymphocyte count, absolute neutrophil count and haemoglobin as continuous variables.
results

muscle-invasive bladder cancer
The baseline characteristics of the muscle-invasive cohort are listed in Table 1 . There was no significant difference in the distribution of prognostic factors between the lymphocytopaenic and the non-lymphocytopaenic groups ( Table 1) . Disease-free survival in the whole population was 77% with 17/74 patients developing invasive local recurrence or metastatic disease. The median absolute lymphocyte count was significantly lower in patients with disease recurrence (1.4 × 10 9 /l, 95% CI 1.2-2.0) than in those without recurrence (1.8 × 10 9 /l, 95% CI 1.7-2.0; P = 0.02). ROC curve analysis determined an absolute lymphocyte count of 1.45 × 10 9 /l to be the optimal cut-off (area under the curve = 0.67). Since the lower limit of normal range was 1.5 × 10 9 /l, it was selected as the cut-off value to define lymphocytopaenia. Table 2 lists the effect of the clinicopathological prognostic variables in both univariate and multivariate analyses. Figure 1 illustrates the survival curves for lymphocytopaenia as a prognostic factor in this cohort. On univariate analysis, lymphocytopaenia, neutrophilia and anaemia were significant adverse prognostic factors. However, in the multivariate model, only lymphocytopaenia was associated with inferior disease-free survival.
advanced bladder cancer
The baseline characteristics of the advanced bladder cohort are listed in Table 3 . While using the cut-off derived from the muscle-invasive bladder cancer cohort, the proportion of patients with pre-treatment lymphocytopaenia was significantly higher in this cohort. (77/131 versus 22/74; z test for proportions, P = 0.00006). Kaplan-Meier survival analysis ( Figure 2 ) showed a significantly worse outcome for the low absolute lymphocyte count group (HR 1.9, 95% CI 1.3-2.8; log-rank test P = 0.0005). The median overall survival was 7.5 months (range (Table 3 ). However, on multivariate analysis in a continuous variable model, only the absolute lymphocyte count retained significance as a prognostic factor, whereas in the dichotomized model, pre-treatment lymphocytopaenia and performance status were significant factors (Tables 4 and 5 ).
discussion This is the first study to show that lymphocytopaenia is an independent prognostic factor in both muscle-invasive bladder cancer patients treated with radical chemoradiotherapy and advanced bladder cancer patients treated with palliative chemotherapy. In addition, the study showed that absolute lymphocyte count was significant as a continuous variable in the advanced bladder cancer cohort, demonstrating that the magnitude of lymphocytopaenia correlates with inferior outcome. A related biomarker, the neutrophil-lymphocyte ratio has been studied in many tumours including bladder cancer, with a high ratio being associated with an inferior outcome [12] [13] [14] . In our study, neutrophilia was prognostic on univariate analysis but not in the multivariable models of both cohorts, suggesting that the prognostic value of a high neutrophil-lymphocyte ratio may actually be driven by lymphocytopaenia rather than neutrophilia in our groups of patients. In addition, there has been no consistency in the cut-off for the neutrophil-lymphocyte ratio with values ranging from 2 to 5 being used in the reported studies, making it less reliable as a valid prognostic factor [12] . A single study on inflammatory markers in a cohort of patients with both superficial and muscle-invasive bladder cancer who underwent radical cystectomy revealed an absolute lymphocyte count <1.0 × 10 9 as an independent prognostic marker together with low albumin, high platelet count and tumour stage [15] . This is yet to be validated in an independent cohort. Neutrophilia and high C-reactive protein were not significant in the model, suggesting a reduced role for inflammation. It may be, however, that lymphocytopaenia is a manifestation of cancer-induced immune suppression.
The causes of tumour-induced lymphocytopaenia remain to be fully elucidated, but are believed to be the result of impaired lymphocyte homeostasis and enhanced lymphocyte apoptosis. Increased secretion of transforming growth factor (TGF)-β by the tumour and its microenvironment impairs the activation of effector cytotoxic and helper lymphocytes while promoting the recruitment of suppressive regulatory T cells [16] . Tumour cells also express higher levels of pro-apoptotic molecules such as Fas ligand and programmed death-1 ligand-1 (PD-L1) resulting in increased destruction of cytotoxic lymphocytes via activation of the extrinsic pathway of apoptosis [17] . Since many of the pathways that lead to tumour immune escape may also facilitate lymphocytopaenia, it may be a surrogate marker of tumourassociated immune suppression.
Tumour necrosis, a histopathological end point in hypoxia, was shown to be a prognostic and predictive biomarker in the BCON trial, which tested the addition of carbogen and nicotinamide in muscle-invasive bladder cancer patients referred for radical radiotherapy either as part of a bladder preservation approach or if considered unsuitable for radical surgery [18] . The expression of hypoxia-associated proteins such as hypoxia-inducible factor (HIF)-1α is also associated with a poor prognosis [19] . Studies are needed to increase our understanding of the effect of tumour hypoxia on the immune system [20] . Some studies have shown that expression of HIF-1α as well as production of TGF-β in response to hypoxia results in an increase in regulatory T cells in the tumour microenvironment leading to a state of immunosuppression [20] [21] [22] . The significant association between anaemia and lymphocytopaenia in our study raises the possibility of a causal nexus between tumour hypoxia and suppressed anti-tumour immunity leading to a more aggressive disease phenotype.
If cancer-induced immune suppression is a driver of tumour progression, therapeutic modalities directed towards restoring anti-tumour immunity have the potential to improve outcome. It is of note that one of the earliest success stories in antitumour immunotherapy was in superficial bladder cancer with the serendipitous discovery that intravesical Bacillus Calmette-Guérin prevents disease relapse and progression [23] . More recently, PD-L1 was identified as a potential prognostic biomarker, and a phase I trial of an anti-PD-L1 antibody in advanced The statistically significant factors (on multi-variate analysis) have had their p values were denoted in bold. bladder cancer has shown promising efficacy [24] . Restoring lymphocyte homeostasis could lead to activation of effector cytotoxic and helper T cells resulting in a more potent antitumour immune response [25] . Moreover, pre-treatment lymphocytopaenia has the potential to be a predictive biomarker to select patients suitable for therapeutic strategies directed at restoring anti-tumour immunity in bladder cancer. Apart from the limitations inherent in a small study of this nature, post-treatment absolute lymphocyte count could not be assessed as the data were not available for all patients. It would have been interesting to note whether lymphocytopaenia was restored to normality following completion of therapy in the muscle-invasive bladder cancer cohort and whether the postradical chemoradiotherapy absolute lymphocyte count correlated with outcome.
To validate the findings reported here, pre-treatment lymphocytopaenia needs to be tested in an independent cohort of muscle-invasive bladder cancer patients treated with a bladder preservation approach, as well as in a cohort of patients undergoing radical cystectomy. However, we showed that lymphocytopaenia was an independent adverse prognostic factor in two cohorts of patients treated with different approaches and clinical intent. In addition, the increased prevalence of lymphocytopaenia in advanced compared with muscle-invasive bladder cancer further enhances its clinical relevance.
conclusion Pre-treatment lymphocytopaenia is a simple and independent adverse prognostic factor in muscle-invasive and advanced bladder cancer. It may be a manifestation of cancer-induced immune suppression driving tumour progression. Therapeutic agents restoring normal lymphocyte homeostasis may hold considerable promise in bladder cancer.
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